Divestment of Biopharmaceutical Manufacturing Facility
PharmaVentures Divests Manufacturing Facility for Major Pharma Client.
Oxford, UK, 7th July, 2014
PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May, represents a significant success for the major Pharma in implementing its forward strategy and the acquisition of a growth driving capability for the acquirer. This divestment follows multiple divestments of R&D and Manufacturing facilities in the last 4 years for several of the largest pharmaceutical companies. Fintan Walton, CEO, PharmaVentures Ltd commented: “Once again PharmaVentures is delighted to have delivered a successful and valuable outcome for our client and in the process secured hundreds of jobs.” Over the past 22 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.